食管癌患者接受新辅助治疗及食管切除术后的辅助治疗效果。

IF 2.2 4区 医学 Q3 ONCOLOGY
MaoTian Xu, Fei Xu, Jing Luo, Chi Zhang, Yi Shen
{"title":"食管癌患者接受新辅助治疗及食管切除术后的辅助治疗效果。","authors":"MaoTian Xu, Fei Xu, Jing Luo, Chi Zhang, Yi Shen","doi":"10.4149/neo_2025_250307N111","DOIUrl":null,"url":null,"abstract":"<p><p>The application of adjuvant therapy following neoadjuvant treatment and subsequent esophagectomy remains a subject of debate due to the limited availability of comprehensive studies. This study aims to evaluate the role of adjuvant therapy in patients with esophageal adenocarcinoma (EAC) who have undergone neoadjuvant therapy and esophagectomy, thereby offering evidence-based guidance for clinical decision-making. Patients diagnosed with EAC and treated with neoadjuvant therapy followed by surgical intervention were enrolled in our study. The data for patients in the training cohort were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. To validate the findings, new patient cohorts were utilized. A total of 3,445 patients with EAC were identified from the SEER database based on the established eligibility criteria. The analysis revealed no significant differences between the adjuvant therapy group and the non-adjuvant therapy group in terms of 5-year overall survival, with rates of 35.7% and 37.2%, respectively (p=0.920), nor in 5-year cancer-specific survival, with rates of 39.5% and 43.2%, respectively (p=0.520). Additionally, 130 patients were identified from the Affiliated Jinling Hospital of Nanjing University's Medical School. In this cohort, findings indicated that patients receiving adjuvant therapy demonstrated improved overall survival compared to those not receiving such therapy (p=0.031). Leveraging the SEER database, our study demonstrated that adjuvant therapy did not confer a survival advantage for patients with EAC following neoadjuvant therapy and surgery. In contrast, data analysis from the Affiliated Jinling Hospital, Medical School of Nanjing University in China, indicated that EAC patients might indeed benefit from adjuvant therapy after undergoing neoadjuvant treatment and esophagectomy.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":"72 3","pages":"200-210"},"PeriodicalIF":2.2000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adjuvant treatment efficacy in esophageal adenocarcinoma patients receiving neoadjuvant therapy and esophagectomy.\",\"authors\":\"MaoTian Xu, Fei Xu, Jing Luo, Chi Zhang, Yi Shen\",\"doi\":\"10.4149/neo_2025_250307N111\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The application of adjuvant therapy following neoadjuvant treatment and subsequent esophagectomy remains a subject of debate due to the limited availability of comprehensive studies. This study aims to evaluate the role of adjuvant therapy in patients with esophageal adenocarcinoma (EAC) who have undergone neoadjuvant therapy and esophagectomy, thereby offering evidence-based guidance for clinical decision-making. Patients diagnosed with EAC and treated with neoadjuvant therapy followed by surgical intervention were enrolled in our study. The data for patients in the training cohort were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. To validate the findings, new patient cohorts were utilized. A total of 3,445 patients with EAC were identified from the SEER database based on the established eligibility criteria. The analysis revealed no significant differences between the adjuvant therapy group and the non-adjuvant therapy group in terms of 5-year overall survival, with rates of 35.7% and 37.2%, respectively (p=0.920), nor in 5-year cancer-specific survival, with rates of 39.5% and 43.2%, respectively (p=0.520). Additionally, 130 patients were identified from the Affiliated Jinling Hospital of Nanjing University's Medical School. In this cohort, findings indicated that patients receiving adjuvant therapy demonstrated improved overall survival compared to those not receiving such therapy (p=0.031). Leveraging the SEER database, our study demonstrated that adjuvant therapy did not confer a survival advantage for patients with EAC following neoadjuvant therapy and surgery. In contrast, data analysis from the Affiliated Jinling Hospital, Medical School of Nanjing University in China, indicated that EAC patients might indeed benefit from adjuvant therapy after undergoing neoadjuvant treatment and esophagectomy.</p>\",\"PeriodicalId\":19266,\"journal\":{\"name\":\"Neoplasma\",\"volume\":\"72 3\",\"pages\":\"200-210\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neoplasma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4149/neo_2025_250307N111\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neoplasma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4149/neo_2025_250307N111","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

由于全面的研究有限,新辅助治疗和食管切除术后的辅助治疗的应用仍然是一个有争议的话题。本研究旨在评价辅助治疗在食管腺癌(EAC)患者行新辅助治疗及食管切除术中的作用,为临床决策提供循证指导。我们的研究纳入了诊断为EAC并接受新辅助治疗和手术干预的患者。培训队列患者的数据从监测、流行病学和最终结果(SEER)数据库中提取。为了验证研究结果,采用了新的患者队列。根据既定的资格标准,从SEER数据库中共鉴定出3445例EAC患者。分析显示,辅助治疗组与非辅助治疗组5年总生存率无显著差异,分别为35.7%和37.2% (p=0.920), 5年肿瘤特异性生存率分别为39.5%和43.2% (p=0.520)。此外,从南京大学医学院附属金陵医院确定了130例患者。在这个队列中,研究结果表明,接受辅助治疗的患者比未接受辅助治疗的患者总生存率更高(p=0.031)。利用SEER数据库,我们的研究表明,在新辅助治疗和手术后,辅助治疗并没有给EAC患者带来生存优势。相比之下,中国南京大学医学院附属金陵医院的数据分析表明,EAC患者在接受新辅助治疗和食管切除术后确实可能受益于辅助治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Adjuvant treatment efficacy in esophageal adenocarcinoma patients receiving neoadjuvant therapy and esophagectomy.

The application of adjuvant therapy following neoadjuvant treatment and subsequent esophagectomy remains a subject of debate due to the limited availability of comprehensive studies. This study aims to evaluate the role of adjuvant therapy in patients with esophageal adenocarcinoma (EAC) who have undergone neoadjuvant therapy and esophagectomy, thereby offering evidence-based guidance for clinical decision-making. Patients diagnosed with EAC and treated with neoadjuvant therapy followed by surgical intervention were enrolled in our study. The data for patients in the training cohort were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. To validate the findings, new patient cohorts were utilized. A total of 3,445 patients with EAC were identified from the SEER database based on the established eligibility criteria. The analysis revealed no significant differences between the adjuvant therapy group and the non-adjuvant therapy group in terms of 5-year overall survival, with rates of 35.7% and 37.2%, respectively (p=0.920), nor in 5-year cancer-specific survival, with rates of 39.5% and 43.2%, respectively (p=0.520). Additionally, 130 patients were identified from the Affiliated Jinling Hospital of Nanjing University's Medical School. In this cohort, findings indicated that patients receiving adjuvant therapy demonstrated improved overall survival compared to those not receiving such therapy (p=0.031). Leveraging the SEER database, our study demonstrated that adjuvant therapy did not confer a survival advantage for patients with EAC following neoadjuvant therapy and surgery. In contrast, data analysis from the Affiliated Jinling Hospital, Medical School of Nanjing University in China, indicated that EAC patients might indeed benefit from adjuvant therapy after undergoing neoadjuvant treatment and esophagectomy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neoplasma
Neoplasma 医学-肿瘤学
CiteScore
5.40
自引率
0.00%
发文量
238
审稿时长
3 months
期刊介绍: The journal Neoplasma publishes articles on experimental and clinical oncology and cancer epidemiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信